[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-352851-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-352851-en":134},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","nanotechnology-in-triple-negative-breast-cancer-a-review-of-nanocarrier-systems-for-enhanced-efficacy-and-reduced-toxicity","Nanotechnology in triple-negative breast cancer - a review of nanocarrier systems for enhanced efficacy and reduced toxicity","","Triple-negative breast cancer (TNBC) lacks HER2, progesterone, and estrogen receptors, narrowing treatment options and elevating risks of metastasis and recurrence. Diverse tumor microenvironment features, genetic heterogeneity, and inherent drug resistance often make chemotherapy and radiotherapy limited by poor efficacy and severe systemic toxicity. This review examines liposomes, dendrimers, polymeric nanoparticles, and quantum dots for passive/active targeting, stimulus-responsive drug release, ligand/peptide/antibody functionalization, and theranostic monitoring. Clinical translation remains constrained by scalability, regulatory hurdles, and potential immunogenicity.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/nanotechnology-in-triple-negative-breast-cancer-a-review-of-nanocarrier-systems-for-enhanced-efficacy-and-reduced-toxicity/352851/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/nanotechnology-in-triple-negative-breast-cancer-a-review-of-nanocarrier-systems-for-enhanced-efficacy-and-reduced-toxicity/352851.png","ImageObject",300,407,{"name":42,"@type":43},"Bintang","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"Why is treating triple-negative breast cancer particularly challenging?","Question",{"text":63,"@type":64},"TNBC lacks HER2, progesterone, and estrogen receptors, limiting available therapies. Its complex tumor microenvironment, genetic diversity, and innate drug resistance contribute to poor efficacy and severe systemic toxicity with conventional treatments.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which nanocarrier platforms are reviewed for improved TNBC performance?",{"text":68,"@type":64},"The review discusses liposomes, dendrimers, polymeric nanoparticles, and quantum dots. It evaluates how these platforms can target TNBC through passive and active mechanisms.",{"name":70,"@type":61,"acceptedAnswer":71},"How do stimulus-responsive and ligand-functionalized nanocarriers help?",{"text":72,"@type":64},"Stimulus-responsive systems enable regulated drug release. Nanocarriers functionalized with ligands, peptides, and antibodies can enhance selectivity and reduce off-target effects and immune recognition.",{"name":74,"@type":61,"acceptedAnswer":75},"What limits the clinical translation of nanocarrier-based strategies?",{"text":76,"@type":64},"Major barriers include scalability, regulatory obstacles, and possible immunogenicity that complicate moving nanocarrier systems from research to clinical use.","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},352851,1790571759,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,105,110,115,118,123,126,130],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},5,"Comic",60,"comic",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},6,"Technology",50,"technology",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":116,"slug":117},30,"research-report",{"id":119,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":121,"slug":122},9,"Religion & Spirituality",20,"religion-spirituality",{"id":121,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":121,"slug":125},"World Cup","world-cup",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":127,"slug":129},10,"Lifestyle","lifestyle",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":101,"slug":133},19,"General","general",{"code":4,"msg":86,"data":135},{"doc_id":83,"user_id":136,"nickname":42,"user_avatar":137,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":143,"language":144,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":12,"update_tm":148,"read_time":149,"preview_page_count":33,"preview_urls":150},962085564381,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Nanoscale Advances  \nREVIEW  \nCite this: DOI: 10 .1039/d5na00907c  \nReceived 23rd September 2025  \nAccepted 19th February 2026 DOI: 10.1039/d5na00907c[rsc.li/nanoscale-advances](rsc.li/nanoscale-advances)  \nNanotechnology in triple-negative breast cancer: a review of nanocarrier systems for enhanced eﬃcacy and reduced toxicity  \nQazi Saifullah,  a Sajid Mondal,  a Amartya Nandi,  a Yeduvaka Madhuri,  a Suvadra Das b and Partha Roy  *a  \nThe aggressive and extremely diverse subtype of breast cancer known as triple-negative breast cancer(TNBC)lacks HER2, progesterone, and oestrogen receptors, which limits treatment options and increases the risk of metastasis and recurrence. Because of TNBC's complex tumour microenvironment (TME), genetic variety, and innate drug resistance, conventional therapies like chemotherapy and radiotherapy frequently cause severe systemic toxicity and have poor eﬃcacy. By improving targeted delivery, reducing oﬀ-target eﬀects, and facilitating multimodal therapy options, nanocarrier-based drug delivery devices provide a revolutionary strategy for TNBC. The ability of several nanocarrier platforms, such as liposomes, dendrimers, polymeric nanoparticles (NPs), and quantum dots, to target TNBC's distinct TME via passive and active mechanisms is thoroughly examined in this review. Stimulus-responsive systems enable regulated drug release, and nanocarriers functionalised with ligands, peptides, and antibodies have shown enhanced selectivity and decreased immune recognition. Furthermore, theranostic nanocarriers optimise therapeutic outcomes by enabling simultaneous diagnostic and treatment monitoring. Clinical translation is still hampered by important issues like scalability, regulatory obstacles, and possible immunogenicity. The relevance of nanotechnology in improving TNBC treatment is highlighted in this publication, which also addresses these obstacles and new developments intended to overcome them. Nanocarrier-based strategies have the potential to improve patient outcomes in TNBC management with precise control over drug cargo delivery sites and suitable engineering to mitigate the disease.  \naGITAM School of Pharmacy, GITAM (deemed to be University), Rushikonda, Visakhapatnam-530045, Andhra Pradesh, India. E-mail: [proy@gitam.edu](proy@gitam.edu); [partharoy2502@gmail.com](partharoy2502@gmail.com)  \nbBasic Science and Humanities Department, University of Engineering and Management, Kolkata, West Bengal 700160, India  \nQazi Saifullah completed his M. Pharmacy at Chandigarh University, Mohali, in 2023. He is currently pursuing a PhD at GITAM (Deemed to be University), Visakhapatnam, India. His doctoral work focuses on nanomedicine and targeted drug delivery strategies for triple negative breast cancer with an emphasis on designing advanced nanoparticle systems and integrating computational  \napproaches for therapeutic  \nimprovement. His research interests include photopharmacology, nanotechnology-based targeted drug delivery, cancer therapeutics and the development of innovative formulation strategies for complex diseases. He has research experience in organic synthesis, computational and cheminformatics tools, chemical and spectral analysis so􀀁ware and animal handling.  \nSajid Mondal completed his M. Pharmacy in Pharmaceutics atthe GITAM School of Pharmacy, GITAM (Deemed to be University), Visakhapatnam, in 2025.  \nHis current work focuses on the design & optimization of drug delivery systems. During his postgraduate research, he worked on developing an engineered nanoformulation of delamanid aimed at improving therapeutic outcomes in the management of tuberculosis.  \nHis research interests include pharmaceutical nanotechnology, novel drug delivery systems, and formulation development for challenging drug molecules.  \n© 2026 The Author(s) . Published by the Royal Society of Chemistry Nanoscale Adv.  \nNanoscale Advances Review  \n1. Introduction  \nTriple negative breast cancer (TNBC) is the cause of aro","cbCaid1dE6YNtUQ8","https://ap.wps.com/l/cbCaid1dE6YNtUQ8","pdf",1257434,29,"English","# Introduction\n## Nanotechnology-based approaches for TNBC\n## Nanocarrier types and targeting strategies\n## Stimulus-responsive and functionalized carriers\n## Theranostic nanocarriers and clinical translation challenges","[{\"question\":\"Why is treating triple-negative breast cancer particularly challenging?\",\"answer\":\"TNBC lacks HER2, progesterone, and estrogen receptors, limiting available therapies. Its complex tumor microenvironment, genetic diversity, and innate drug resistance contribute to poor efficacy and severe systemic toxicity with conventional treatments.\"},{\"question\":\"Which nanocarrier platforms are reviewed for improved TNBC performance?\",\"answer\":\"The review discusses liposomes, dendrimers, polymeric nanoparticles, and quantum dots. It evaluates how these platforms can target TNBC through passive and active mechanisms.\"},{\"question\":\"How do stimulus-responsive and ligand-functionalized nanocarriers help?\",\"answer\":\"Stimulus-responsive systems enable regulated drug release. Nanocarriers functionalized with ligands, peptides, and antibodies can enhance selectivity and reduce off-target effects and immune recognition.\"},{\"question\":\"What limits the clinical translation of nanocarrier-based strategies?\",\"answer\":\"Major barriers include scalability, regulatory obstacles, and possible immunogenicity that complicate moving nanocarrier systems from research to clinical use.\"}]","Nanotechnology in triple-negative breast cancer - a review of nanocarrier systems for enhanced efficacy and reduced toxicity | PDF",1790101705,73,[151,155,159,163],{"page_no":22,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9227fa45ab9cf983bcd8e2d907c8e9d4.webp",983,1287,{"page_no":26,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/621992b78cb6bb77c4097ca078b4677b.webp",982,1286,{"page_no":30,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/00a637a823f2767a32c7edb80f376ff9.webp",981,1284,{"page_no":33,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e8c03be1ab198ae23cffd26b9bba3dd1.webp",980,1283]